CLARIUS-MOBILE-HEALTH
5.5.2022 09:17:13 CEST | Business Wire | Press release
Clarius Mobile Health is first to introduce a third-generation product line of high-performance wireless ultrasound scanners in the European Union and United Kingdom. Now 30% lighter and smaller, the new pocket-sized scanners that connect with Apple and Android devices are available today with revolutionary pricing and new features that will put premium handheld ultrasound into the hands of more doctors. Clarius has replaced the complex knobs and buttons found on traditional ultrasound systems with an app that uses artificial intelligence and intuitive touch-based controls. Thousands of first and second generation Clarius scanners are already in use across the continent to improve diagnostic speed and accuracy and improve procedural safety.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220505005072/en/
“Clinicians in Europe and the UK have been early adopters of Clarius wireless ultrasound, and we know excitement has been building for our new miniaturized Clarius HD3 because we’ve had a long list of customers eagerly waiting for CE certification,” says Clarius Founder Laurent Pelissier. “Our mission has always been to improve patient care by enabling more clinicians to use ultrasound. Now that Clarius is reduced to the size of an iPhone, easier to use, and costs less, we’re expecting more clinicians will use ultrasound to deliver the best patient care.”
In emergency environments, the Clarius C3 HD3 multipurpose scanner saves lives. Dr. Wolfgang Fleischmann, an anesthesiologist and emergency medicine physician, describes why the Red Cross chose Clarius when it sought to equip its emergency services vehicles with hospital-grade portable ultrasound.
“We had the opportunity to extensively test the Clarius scanner in our prehospital emergency environment. The product impressed us with its image quality, its reliability, its short start-up time, and good price-to-performance ratio. It prompted us to equip all our emergency doctors’ cars and ambulances with the Clarius ultrasound device.”
Clarius sets itself apart from other handheld ultrasound systems with exceptional imaging quality that rivals expensive cart-based systems, wireless connectivity, and specialty scanners with Software-as-a-Service (SaaS) designed to optimize clarity and workflows for different anatomy and applications. Clinicians can choose from seven ultrasound scanners, each designed to meet the specific requirements of a broad range of medical specialties.
With best-in-class MSK imaging, the Clarius L15 HD3 high-frequency linear scanner is a top choice amongst orthopaedic surgeons. Dr. Rudolf Berlakovits, MD, PhD, an orthopaedic surgeon in Vienna, Austria, describes the advantages of the new Clarius HD3 for safe, procedural guidance.
"To me as an orthopedic surgeon, the Clarius HD3 is a highly recommended device for interventional orthopedics and ultrasound guided orthopedic surgery. There is no cable, making it easy to keep aseptic, and the probe provides perfect handling. Another really great benefit is the possibility to share the findings with colleagues all over the world in real-time with Clarius Cloud exam management."
Clarius offers software packages designed for many specialty applications including Advanced Breast , Musculoskeletal , Obstetrics , Primary/Critical Care , Vascular , Veterinary Packages , and Aesthetics . They deliver dedicated presets, advanced workflows, comprehensive measurements, and fined tuned imaging, leveraging artificial intelligence and SaaS to deliver a complete handheld ultrasound solution that’s connected to the cloud.
Dr. Ines Verner, an Aesthetic Dermatologist based in Tel-Aviv, uses the Clarius L20 wireless ultrasound scanner to prevent complications such as vascular occlusions during aesthetic procedures like cosmetic fillers. She was among the first to try the Clarius L20 HD3 for facial aesthetics.
“It’s a breakthrough in the field. Clarius is a good fit for aesthetics because it lets me clearly see fine facial anatomy, it’s easy to use, the image quality is good, it’s wireless, and it’s small so I can take it with me from room to room,” Dr. Verner says. “Ultrasound is a gamechanger for the aesthetics industry because we can really see what we need to see instead of injecting blindly, which is what most of us used to do. Now, we can inject knowing where we’re going and not to inject where we don’t want to inject.”
New Membership Enables Ultrasound Mastery at a Lower Price
Clarius has introduced a new Clarius Membership bundle that makes the entry price lower and enables new users to fast-track ultrasound proficiency. Clarius HD3 wireless scanners now start at 2875 EUR with a 575 annual membership in Europe or 2440 GBP with 490 membership annual membership in the United Kingdom. Members gain access to all advanced SaaS, enhanced education options, and unlimited exam management in the Clarius Cloud. A three-year standard warranty is included with enhanced warranty options available through Clarius Care.
About Clarius Mobile Health
Clarius is on a mission to make accurate, easy-to-use, and affordable ultrasound tools available to all medical professionals in every specialty. Clarius handheld wireless ultrasound scanners connect to iOS and Android devices, delivering high-resolution ultrasound images traditionally only available with bulkier, high-end systems at a fraction of the cost. More than two million high-definition scans have been performed using Clarius wireless handheld scanners. Clarius scanners are available in over 90 countries worldwide. Learn more at www.clarius.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005072/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
